CHAF1A expression alone could predict the immunotherapy response, but its CS with EBV infection, MSI, TMB, or PD-L1 expression showed better effects and improved response stratification based on current biomarkers. The gene discussed is CHAF1A; the disease is Epstein-Barr virus infection.